| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simian virus 40 | 146 | 2019 | 202 | 15.770 |
Why?
|
| Polyomavirus Infections | 42 | 2019 | 88 | 8.040 |
Why?
|
| Tumor Virus Infections | 38 | 2016 | 135 | 6.610 |
Why?
|
| DNA, Viral | 72 | 2014 | 492 | 3.870 |
Why?
|
| Antigens, Polyomavirus Transforming | 40 | 2018 | 89 | 3.440 |
Why?
|
| Polyomavirus | 15 | 2014 | 33 | 2.080 |
Why?
|
| Antibodies, Viral | 24 | 2019 | 1131 | 1.810 |
Why?
|
| JC Virus | 13 | 2014 | 29 | 1.740 |
Why?
|
| Antigens, Viral, Tumor | 26 | 2016 | 51 | 1.650 |
Why?
|
| BK Virus | 13 | 2014 | 58 | 1.610 |
Why?
|
| Cell Transformation, Viral | 25 | 2018 | 107 | 1.520 |
Why?
|
| Lymphoma, Non-Hodgkin | 10 | 2007 | 162 | 1.480 |
Why?
|
| Polymerase Chain Reaction | 28 | 2014 | 1592 | 1.430 |
Why?
|
| Neoplasms | 22 | 2012 | 2753 | 1.260 |
Why?
|
| Mammary Neoplasms, Experimental | 29 | 2001 | 245 | 1.230 |
Why?
|
| RNA, Viral | 15 | 2018 | 540 | 1.160 |
Why?
|
| Base Sequence | 44 | 2014 | 3109 | 1.010 |
Why?
|
| Mammary Tumor Virus, Mouse | 21 | 1995 | 106 | 0.970 |
Why?
|
| Drug Contamination | 11 | 2012 | 36 | 0.970 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 12 | 2010 | 167 | 0.960 |
Why?
|
| Antibodies, Neutralizing | 3 | 2019 | 454 | 0.940 |
Why?
|
| Lymphoma | 5 | 2009 | 323 | 0.920 |
Why?
|
| Cell Line | 65 | 2018 | 2782 | 0.910 |
Why?
|
| Molecular Sequence Data | 40 | 2016 | 3865 | 0.890 |
Why?
|
| Lymphoma, AIDS-Related | 4 | 2005 | 37 | 0.860 |
Why?
|
| Genes, Viral | 25 | 2005 | 186 | 0.850 |
Why?
|
| Virus Shedding | 6 | 2014 | 79 | 0.840 |
Why?
|
| Animals | 154 | 2016 | 33723 | 0.760 |
Why?
|
| Genome, Viral | 8 | 2018 | 171 | 0.730 |
Why?
|
| Oncogenic Viruses | 8 | 2012 | 17 | 0.730 |
Why?
|
| MicroRNAs | 3 | 2018 | 839 | 0.720 |
Why?
|
| Mammary Glands, Animal | 18 | 2001 | 482 | 0.720 |
Why?
|
| Cell Transformation, Neoplastic | 34 | 2007 | 630 | 0.720 |
Why?
|
| Hepatitis B virus | 12 | 1998 | 142 | 0.710 |
Why?
|
| Antigens, Viral | 24 | 2008 | 441 | 0.690 |
Why?
|
| Cricetinae | 34 | 2014 | 403 | 0.680 |
Why?
|
| Herpesvirus 4, Human | 6 | 2009 | 663 | 0.680 |
Why?
|
| Genes, p53 | 10 | 1998 | 215 | 0.670 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2019 | 4 | 0.660 |
Why?
|
| HIV Infections | 8 | 2010 | 1858 | 0.660 |
Why?
|
| Genetic Variation | 9 | 2012 | 1462 | 0.650 |
Why?
|
| Brain Neoplasms | 9 | 2004 | 1222 | 0.650 |
Why?
|
| Trans-Activators | 11 | 2001 | 804 | 0.640 |
Why?
|
| Viral Proteins | 20 | 1998 | 348 | 0.610 |
Why?
|
| Viral Load | 8 | 2014 | 380 | 0.610 |
Why?
|
| Papillomavirus Infections | 5 | 1999 | 271 | 0.610 |
Why?
|
| Poliovirus Vaccines | 5 | 2003 | 14 | 0.600 |
Why?
|
| Cell Nucleus | 23 | 1993 | 678 | 0.570 |
Why?
|
| Mice, Inbred BALB C | 38 | 2005 | 980 | 0.560 |
Why?
|
| Poliovirus Vaccine, Inactivated | 5 | 2005 | 12 | 0.560 |
Why?
|
| Feces | 3 | 2014 | 699 | 0.550 |
Why?
|
| Haplorhini | 24 | 2008 | 127 | 0.530 |
Why?
|
| Lymphocytes | 1 | 2018 | 403 | 0.530 |
Why?
|
| Humans | 118 | 2019 | 122292 | 0.520 |
Why?
|
| Kidney Transplantation | 5 | 2012 | 621 | 0.510 |
Why?
|
| Neoplasms, Experimental | 17 | 2004 | 215 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2003 | 712 | 0.490 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2009 | 237 | 0.490 |
Why?
|
| Liver Neoplasms | 14 | 2005 | 1386 | 0.490 |
Why?
|
| Mesocricetus | 10 | 2014 | 68 | 0.490 |
Why?
|
| Mesothelioma | 5 | 2007 | 77 | 0.480 |
Why?
|
| B-Lymphocytes | 3 | 2018 | 517 | 0.480 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2009 | 284 | 0.460 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 62 | 0.460 |
Why?
|
| Seroepidemiologic Studies | 6 | 2019 | 114 | 0.450 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 10 | 1996 | 368 | 0.440 |
Why?
|
| Adenoviridae | 25 | 1986 | 637 | 0.440 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2014 | 233 | 0.440 |
Why?
|
| Mice | 71 | 2007 | 17548 | 0.430 |
Why?
|
| Lymph Nodes | 4 | 2010 | 376 | 0.430 |
Why?
|
| Pleural Neoplasms | 3 | 2007 | 62 | 0.430 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2003 | 265 | 0.430 |
Why?
|
| Mutation | 29 | 2018 | 5734 | 0.420 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 1998 | 957 | 0.410 |
Why?
|
| Antigens, Neoplasm | 17 | 1985 | 386 | 0.400 |
Why?
|
| Biodiversity | 1 | 2012 | 64 | 0.400 |
Why?
|
| Cells, Cultured | 21 | 2018 | 3074 | 0.400 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2007 | 297 | 0.390 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 758 | 0.380 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2003 | 223 | 0.380 |
Why?
|
| Macaca mulatta | 4 | 2014 | 493 | 0.380 |
Why?
|
| Creatinine | 2 | 2012 | 379 | 0.380 |
Why?
|
| Female | 69 | 2019 | 64882 | 0.370 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2012 | 190 | 0.370 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2010 | 12 | 0.360 |
Why?
|
| Oncogene Proteins, Viral | 7 | 1992 | 55 | 0.360 |
Why?
|
| Hodgkin Disease | 3 | 2005 | 293 | 0.350 |
Why?
|
| Gene Expression Regulation, Viral | 5 | 2014 | 135 | 0.340 |
Why?
|
| HIV-1 | 6 | 2005 | 463 | 0.340 |
Why?
|
| Space Flight | 3 | 2009 | 116 | 0.340 |
Why?
|
| Adult | 28 | 2019 | 28730 | 0.330 |
Why?
|
| Precancerous Conditions | 8 | 1998 | 287 | 0.330 |
Why?
|
| Carrier State | 1 | 2009 | 76 | 0.320 |
Why?
|
| Hepatitis B | 3 | 1996 | 162 | 0.310 |
Why?
|
| Bone Neoplasms | 5 | 2003 | 428 | 0.310 |
Why?
|
| Middle Aged | 24 | 2016 | 25636 | 0.300 |
Why?
|
| Virus Activation | 3 | 2003 | 86 | 0.300 |
Why?
|
| Male | 40 | 2019 | 59517 | 0.290 |
Why?
|
| Virus Replication | 25 | 2014 | 603 | 0.290 |
Why?
|
| Amino Acid Sequence | 15 | 2016 | 2674 | 0.280 |
Why?
|
| Sequence Homology, Nucleic Acid | 6 | 2008 | 286 | 0.270 |
Why?
|
| DNA, Neoplasm | 9 | 1998 | 303 | 0.270 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 323 | 0.260 |
Why?
|
| Cell Division | 13 | 2005 | 795 | 0.260 |
Why?
|
| Genes | 7 | 1991 | 443 | 0.250 |
Why?
|
| Cell Membrane | 13 | 1989 | 459 | 0.250 |
Why?
|
| Gamma Rays | 1 | 2005 | 49 | 0.250 |
Why?
|
| DNA Repair | 4 | 1998 | 583 | 0.250 |
Why?
|
| Texas | 7 | 2012 | 3528 | 0.250 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2003 | 230 | 0.250 |
Why?
|
| Open Reading Frames | 4 | 1995 | 211 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 9 | 2014 | 1750 | 0.250 |
Why?
|
| Meningioma | 2 | 2004 | 110 | 0.240 |
Why?
|
| Oncogenes | 5 | 2000 | 172 | 0.240 |
Why?
|
| Phylogeny | 3 | 2016 | 681 | 0.230 |
Why?
|
| Medical Laboratory Personnel | 1 | 2004 | 10 | 0.230 |
Why?
|
| Transfection | 7 | 2001 | 1076 | 0.230 |
Why?
|
| Laboratories, Hospital | 1 | 2004 | 18 | 0.230 |
Why?
|
| Choroid Plexus Neoplasms | 4 | 1998 | 15 | 0.230 |
Why?
|
| Epithelial Cells | 9 | 2010 | 907 | 0.230 |
Why?
|
| DNA Primers | 7 | 2008 | 668 | 0.230 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1033 | 0.220 |
Why?
|
| Adolescent | 13 | 2019 | 18939 | 0.220 |
Why?
|
| HIV Seronegativity | 3 | 2005 | 25 | 0.220 |
Why?
|
| Plasmids | 8 | 2005 | 516 | 0.220 |
Why?
|
| Conserved Sequence | 4 | 2005 | 291 | 0.220 |
Why?
|
| Transcriptional Activation | 4 | 2001 | 483 | 0.220 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 1996 | 66 | 0.220 |
Why?
|
| DNA Replication | 9 | 1997 | 345 | 0.210 |
Why?
|
| Virion | 1 | 2003 | 149 | 0.210 |
Why?
|
| Proto-Oncogenes | 5 | 2001 | 37 | 0.210 |
Why?
|
| Genes, Regulator | 2 | 2002 | 56 | 0.210 |
Why?
|
| Osteosarcoma | 4 | 1998 | 258 | 0.210 |
Why?
|
| Capsid Proteins | 3 | 2016 | 183 | 0.210 |
Why?
|
| Carcinogens | 3 | 2000 | 152 | 0.210 |
Why?
|
| Kidney | 21 | 2012 | 1340 | 0.210 |
Why?
|
| Heat-Shock Proteins | 3 | 1994 | 194 | 0.210 |
Why?
|
| Viral Regulatory and Accessory Proteins | 8 | 1998 | 44 | 0.200 |
Why?
|
| Incidence | 7 | 2007 | 3018 | 0.200 |
Why?
|
| Gene Expression | 5 | 2005 | 1579 | 0.200 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 1993 | 138 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2001 | 557 | 0.200 |
Why?
|
| Membrane Proteins | 6 | 1995 | 1520 | 0.200 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 68 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 269 | 0.190 |
Why?
|
| HIV Seropositivity | 2 | 2002 | 116 | 0.190 |
Why?
|
| Immunocompromised Host | 4 | 2014 | 300 | 0.180 |
Why?
|
| Zebrafish Proteins | 1 | 2001 | 104 | 0.180 |
Why?
|
| Virus Cultivation | 10 | 1995 | 76 | 0.180 |
Why?
|
| Fibroblast Growth Factors | 1 | 2001 | 153 | 0.180 |
Why?
|
| Gene Deletion | 2 | 1994 | 799 | 0.180 |
Why?
|
| Kidney Diseases | 3 | 2012 | 477 | 0.180 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 268 | 0.180 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 421 | 0.170 |
Why?
|
| Monkey Diseases | 2 | 2008 | 19 | 0.170 |
Why?
|
| Antibody Formation | 7 | 2009 | 255 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2001 | 120 | 0.170 |
Why?
|
| Ependymoma | 3 | 1998 | 134 | 0.170 |
Why?
|
| Mass Media | 1 | 2000 | 28 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 1992 | 368 | 0.170 |
Why?
|
| alpha 1-Antitrypsin | 2 | 1990 | 97 | 0.170 |
Why?
|
| Protein Kinases | 3 | 1986 | 329 | 0.170 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 247 | 0.160 |
Why?
|
| Nicaragua | 1 | 2019 | 26 | 0.160 |
Why?
|
| Colombia | 1 | 2019 | 48 | 0.160 |
Why?
|
| Biological Transport | 12 | 1987 | 347 | 0.160 |
Why?
|
| DNA Restriction Enzymes | 5 | 1997 | 121 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 51 | 0.160 |
Why?
|
| Lung Transplantation | 3 | 2009 | 316 | 0.160 |
Why?
|
| Urine | 4 | 2010 | 88 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 252 | 0.160 |
Why?
|
| Erythrocebus patas | 1 | 1998 | 4 | 0.150 |
Why?
|
| Breast Neoplasms | 3 | 2002 | 2480 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 229 | 0.150 |
Why?
|
| Chromosome Mapping | 7 | 1994 | 1067 | 0.150 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2018 | 16 | 0.150 |
Why?
|
| Sequence Alignment | 3 | 2005 | 613 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 25 | 1985 | 461 | 0.150 |
Why?
|
| Macaca | 1 | 1998 | 61 | 0.150 |
Why?
|
| Binding Sites | 7 | 2014 | 1292 | 0.150 |
Why?
|
| Spleen | 3 | 2009 | 283 | 0.150 |
Why?
|
| Viral Envelope Proteins | 4 | 1995 | 151 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2018 | 100 | 0.140 |
Why?
|
| Logistic Models | 2 | 2012 | 1772 | 0.140 |
Why?
|
| Glycoproteins | 3 | 1991 | 371 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2009 | 3301 | 0.140 |
Why?
|
| DNA-Binding Proteins | 6 | 1998 | 2029 | 0.140 |
Why?
|
| Young Adult | 4 | 2019 | 8759 | 0.140 |
Why?
|
| Child | 11 | 2019 | 24063 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2019 | 4643 | 0.140 |
Why?
|
| Models, Biological | 4 | 2012 | 1438 | 0.140 |
Why?
|
| Diethylnitrosamine | 1 | 1996 | 18 | 0.130 |
Why?
|
| Alkylating Agents | 1 | 1996 | 14 | 0.130 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1996 | 62 | 0.130 |
Why?
|
| Blotting, Southern | 5 | 2003 | 217 | 0.130 |
Why?
|
| Culture Techniques | 11 | 2003 | 91 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2018 | 419 | 0.130 |
Why?
|
| Cytoplasm | 8 | 1985 | 291 | 0.130 |
Why?
|
| Molecular Weight | 12 | 1997 | 390 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 816 | 0.130 |
Why?
|
| Heterozygote | 4 | 1994 | 675 | 0.130 |
Why?
|
| Prevalence | 3 | 2009 | 2371 | 0.130 |
Why?
|
| Neutralization Tests | 5 | 2005 | 238 | 0.130 |
Why?
|
| Vaccination | 2 | 2019 | 927 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2008 | 204 | 0.120 |
Why?
|
| Antigens, Surface | 4 | 1984 | 122 | 0.120 |
Why?
|
| Pregnancy | 11 | 2014 | 7092 | 0.120 |
Why?
|
| Viral Plaque Assay | 5 | 2004 | 42 | 0.120 |
Why?
|
| Italy | 1 | 2014 | 110 | 0.120 |
Why?
|
| Peptides | 3 | 2016 | 798 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2009 | 1710 | 0.120 |
Why?
|
| Neoplasm Transplantation | 11 | 2000 | 375 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2005 | 1118 | 0.120 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 805 | 0.110 |
Why?
|
| Cloning, Molecular | 6 | 1997 | 887 | 0.110 |
Why?
|
| Aged | 7 | 2016 | 18783 | 0.110 |
Why?
|
| Capsid | 4 | 1998 | 143 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2014 | 178 | 0.110 |
Why?
|
| Antigens | 14 | 1971 | 156 | 0.110 |
Why?
|
| Clone Cells | 13 | 1998 | 167 | 0.110 |
Why?
|
| Protein Conformation | 6 | 1997 | 831 | 0.110 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 10 | 2000 | 56 | 0.110 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 30 | 0.110 |
Why?
|
| Recombination, Genetic | 5 | 2007 | 445 | 0.100 |
Why?
|
| Time Factors | 6 | 2009 | 6181 | 0.100 |
Why?
|
| Phosphoproteins | 4 | 1990 | 400 | 0.100 |
Why?
|
| Virology | 2 | 2010 | 31 | 0.100 |
Why?
|
| Epithelium | 6 | 1995 | 372 | 0.100 |
Why?
|
| Caseins | 5 | 1992 | 62 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 515 | 0.100 |
Why?
|
| Epitopes | 5 | 1992 | 427 | 0.100 |
Why?
|
| Hyperplasia | 4 | 1995 | 214 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 812 | 0.090 |
Why?
|
| Hospitalization | 1 | 1999 | 1727 | 0.090 |
Why?
|
| Palatine Tonsil | 2 | 2008 | 34 | 0.090 |
Why?
|
| Nova Scotia | 1 | 2010 | 3 | 0.090 |
Why?
|
| Neoplasm Proteins | 4 | 1999 | 666 | 0.090 |
Why?
|
| Protein Binding | 2 | 1998 | 1732 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2001 | 4510 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 5 | 2003 | 268 | 0.090 |
Why?
|
| Alleles | 3 | 1994 | 1579 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2313 | 0.090 |
Why?
|
| Viral Vaccines | 2 | 2012 | 322 | 0.090 |
Why?
|
| Cocarcinogenesis | 2 | 2007 | 23 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2010 | 0.090 |
Why?
|
| Helper Viruses | 7 | 1978 | 55 | 0.090 |
Why?
|
| Fibroblasts | 6 | 2007 | 878 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 6289 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 6 | 1990 | 312 | 0.090 |
Why?
|
| Phenotype | 8 | 2001 | 4150 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 1614 | 0.090 |
Why?
|
| Disease Susceptibility | 3 | 2002 | 298 | 0.090 |
Why?
|
| Ribonuclease P | 1 | 2009 | 9 | 0.080 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 23 | 0.080 |
Why?
|
| Retinoblastoma Protein | 2 | 2003 | 76 | 0.080 |
Why?
|
| Rabbits | 8 | 2016 | 716 | 0.080 |
Why?
|
| Transformation, Genetic | 2 | 1987 | 36 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1991 | 241 | 0.080 |
Why?
|
| Transcription, Genetic | 6 | 2001 | 1703 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2002 | 274 | 0.080 |
Why?
|
| Butanols | 1 | 1989 | 2 | 0.080 |
Why?
|
| Bed Rest | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mice, Transgenic | 7 | 1997 | 2440 | 0.080 |
Why?
|
| Nervous System Neoplasms | 1 | 1988 | 11 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 1998 | 1076 | 0.080 |
Why?
|
| Bird Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Virus Physiological Phenomena | 1 | 2008 | 14 | 0.080 |
Why?
|
| Pharyngeal Diseases | 1 | 2008 | 17 | 0.080 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1988 | 80 | 0.080 |
Why?
|
| Papio | 1 | 2008 | 66 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 645 | 0.080 |
Why?
|
| Birds | 1 | 2008 | 85 | 0.080 |
Why?
|
| Ganglioneuroma | 2 | 1998 | 18 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2016 | 751 | 0.080 |
Why?
|
| Child, Preschool | 7 | 2008 | 13777 | 0.080 |
Why?
|
| Protein Biosynthesis | 5 | 1991 | 668 | 0.080 |
Why?
|
| Asbestos | 1 | 2007 | 14 | 0.070 |
Why?
|
| Choroid Plexus | 1 | 1987 | 23 | 0.070 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1987 | 16 | 0.070 |
Why?
|
| Oligonucleotide Probes | 2 | 2005 | 85 | 0.070 |
Why?
|
| Concanavalin A | 2 | 2005 | 15 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2008 | 270 | 0.070 |
Why?
|
| Species Specificity | 5 | 2004 | 550 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2008 | 384 | 0.070 |
Why?
|
| Brain | 3 | 2009 | 2937 | 0.070 |
Why?
|
| Carcinoma | 1 | 1989 | 282 | 0.070 |
Why?
|
| Risk Factors | 3 | 2012 | 9901 | 0.070 |
Why?
|
| Temperature | 8 | 1978 | 304 | 0.070 |
Why?
|
| Virus Integration | 2 | 1999 | 44 | 0.070 |
Why?
|
| Gene Rearrangement | 1 | 2007 | 316 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 1989 | 2534 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 1250 | 0.060 |
Why?
|
| Methylation | 5 | 1990 | 229 | 0.060 |
Why?
|
| Whole-Body Irradiation | 1 | 2005 | 66 | 0.060 |
Why?
|
| Cytokines | 2 | 2009 | 1272 | 0.060 |
Why?
|
| Kazakhstan | 1 | 2005 | 8 | 0.060 |
Why?
|
| Glycosylation | 3 | 1991 | 110 | 0.060 |
Why?
|
| Virus Latency | 1 | 2005 | 61 | 0.060 |
Why?
|
| Defective Viruses | 5 | 1978 | 19 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2005 | 228 | 0.060 |
Why?
|
| Placenta | 1 | 2009 | 487 | 0.060 |
Why?
|
| Infant | 6 | 2014 | 12302 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 250 | 0.060 |
Why?
|
| Liver | 2 | 1997 | 1851 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 333 | 0.060 |
Why?
|
| Papillomaviridae | 6 | 1986 | 135 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2797 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 201 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2010 | 139 | 0.060 |
Why?
|
| Denmark | 1 | 2003 | 31 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 1994 | 54 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2000 | 1001 | 0.050 |
Why?
|
| Gadolinium | 1 | 2004 | 102 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1995 | 189 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2003 | 18 | 0.050 |
Why?
|
| Hungary | 1 | 2003 | 7 | 0.050 |
Why?
|
| DNA | 5 | 1992 | 1606 | 0.050 |
Why?
|
| Cytochalasin B | 2 | 1984 | 9 | 0.050 |
Why?
|
| Czech Republic | 1 | 2003 | 10 | 0.050 |
Why?
|
| Age Factors | 2 | 2003 | 2777 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 1283 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2001 | 321 | 0.050 |
Why?
|
| Histocompatibility Antigens | 2 | 1973 | 18 | 0.050 |
Why?
|
| Genotype | 2 | 2003 | 2525 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2004 | 12043 | 0.050 |
Why?
|
| Genetic Vectors | 4 | 1995 | 969 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 34 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 53 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2003 | 105 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2005 | 508 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2003 | 102 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 702 | 0.050 |
Why?
|
| Saliva | 1 | 2003 | 113 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2003 | 156 | 0.050 |
Why?
|
| China | 4 | 1992 | 224 | 0.050 |
Why?
|
| Transplants | 1 | 2002 | 36 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 654 | 0.050 |
Why?
|
| Adenoviruses, Human | 2 | 1986 | 82 | 0.050 |
Why?
|
| Immune System | 1 | 2003 | 86 | 0.050 |
Why?
|
| Apoptosis | 3 | 1998 | 1790 | 0.050 |
Why?
|
| Hybridization, Genetic | 5 | 1984 | 20 | 0.050 |
Why?
|
| Luciferases | 2 | 2000 | 137 | 0.050 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2001 | 11 | 0.050 |
Why?
|
| Leucovorin | 1 | 2002 | 50 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 22 | 0.050 |
Why?
|
| Cytopathogenic Effect, Viral | 4 | 1995 | 29 | 0.050 |
Why?
|
| Methionine | 3 | 1988 | 102 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2005 | 3229 | 0.050 |
Why?
|
| Wnt1 Protein | 1 | 2001 | 71 | 0.050 |
Why?
|
| Bleomycin | 1 | 2002 | 150 | 0.050 |
Why?
|
| Seasons | 1 | 2003 | 300 | 0.050 |
Why?
|
| Cytosine | 3 | 1987 | 56 | 0.050 |
Why?
|
| Urban Health | 1 | 2001 | 71 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 273 | 0.050 |
Why?
|
| Cell Cycle | 3 | 1994 | 618 | 0.050 |
Why?
|
| Vincristine | 1 | 2002 | 208 | 0.050 |
Why?
|
| Templates, Genetic | 2 | 1997 | 95 | 0.050 |
Why?
|
| Cadherins | 1 | 2001 | 164 | 0.050 |
Why?
|
| Wnt Proteins | 1 | 2001 | 199 | 0.050 |
Why?
|
| Immunization | 3 | 2009 | 302 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2002 | 307 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2003 | 381 | 0.040 |
Why?
|
| beta Catenin | 1 | 2001 | 208 | 0.040 |
Why?
|
| Complement Fixation Tests | 8 | 1979 | 33 | 0.040 |
Why?
|
| Switzerland | 1 | 2000 | 18 | 0.040 |
Why?
|
| Kinetics | 4 | 1991 | 1315 | 0.040 |
Why?
|
| Finland | 1 | 2000 | 41 | 0.040 |
Why?
|
| Lactation | 3 | 1989 | 185 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 1991 | 172 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2009 | 5962 | 0.040 |
Why?
|
| Methotrexate | 1 | 2002 | 341 | 0.040 |
Why?
|
| Immune Sera | 4 | 1985 | 93 | 0.040 |
Why?
|
| Precipitin Tests | 3 | 1989 | 153 | 0.040 |
Why?
|
| Transplantation Immunology | 4 | 1973 | 54 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 422 | 0.040 |
Why?
|
| Tubulin | 2 | 1991 | 102 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 304 | 0.040 |
Why?
|
| DNA Probes | 2 | 1989 | 125 | 0.040 |
Why?
|
| Cycloheximide | 3 | 1988 | 43 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 384 | 0.040 |
Why?
|
| Oncogene Proteins | 2 | 1990 | 140 | 0.040 |
Why?
|
| RNA, Messenger | 6 | 1992 | 2826 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 355 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2000 | 132 | 0.040 |
Why?
|
| Wilms Tumor | 1 | 1999 | 112 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 1998 | 85 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1998 | 81 | 0.040 |
Why?
|
| Hepadnaviridae | 1 | 1997 | 3 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 1998 | 122 | 0.040 |
Why?
|
| Sequence Homology | 1 | 1997 | 62 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 31 | 0.040 |
Why?
|
| Retroviridae Proteins | 2 | 1987 | 13 | 0.040 |
Why?
|
| Hydrocortisone | 3 | 1992 | 215 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 50 | 0.040 |
Why?
|
| Age Distribution | 1 | 1998 | 400 | 0.040 |
Why?
|
| H-2 Antigens | 3 | 1998 | 24 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 4282 | 0.030 |
Why?
|
| Galactose | 2 | 1988 | 55 | 0.030 |
Why?
|
| Leukocytes | 1 | 1998 | 204 | 0.030 |
Why?
|
| Microscopy, Electron | 6 | 1980 | 400 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 3292 | 0.030 |
Why?
|
| Photoreceptor Cells | 1 | 1997 | 89 | 0.030 |
Why?
|
| Transcription Factor AP-2 | 1 | 1996 | 20 | 0.030 |
Why?
|
| Cell Differentiation | 4 | 1990 | 1935 | 0.030 |
Why?
|
| Embryo, Mammalian | 6 | 1986 | 452 | 0.030 |
Why?
|
| Genomics | 1 | 2004 | 1458 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1997 | 131 | 0.030 |
Why?
|
| Gene Products, tax | 1 | 1996 | 46 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 1369 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2007 | 15853 | 0.030 |
Why?
|
| Genetics, Microbial | 3 | 1972 | 5 | 0.030 |
Why?
|
| Phosphorylation | 4 | 1986 | 1613 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 1996 | 48 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1997 | 159 | 0.030 |
Why?
|
| Cell Compartmentation | 2 | 1986 | 42 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 1977 | 178 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 1997 | 264 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 2014 | 523 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Genes, tat | 1 | 1995 | 10 | 0.030 |
Why?
|
| Superantigens | 1 | 1995 | 19 | 0.030 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 2 | 1985 | 3 | 0.030 |
Why?
|
| Acetylglucosaminidase | 2 | 1985 | 17 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 260 | 0.030 |
Why?
|
| Adenoviruses, Simian | 1 | 1975 | 1 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1999 | 426 | 0.030 |
Why?
|
| Yeasts | 1 | 1995 | 42 | 0.030 |
Why?
|
| Locus Control Region | 1 | 2014 | 8 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 5013 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1998 | 506 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2006 | 2996 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1996 | 808 | 0.030 |
Why?
|
| Phosphopeptides | 2 | 1984 | 27 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 3 | 1992 | 1022 | 0.030 |
Why?
|
| Mumps | 1 | 1974 | 11 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 1994 | 13 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 6 | 1983 | 397 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1994 | 129 | 0.030 |
Why?
|
| Prolactin | 2 | 1992 | 104 | 0.030 |
Why?
|
| Multigene Family | 1 | 1995 | 299 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 145 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1996 | 1679 | 0.030 |
Why?
|
| Ultraviolet Rays | 4 | 1998 | 204 | 0.030 |
Why?
|
| Lens, Crystalline | 1 | 1994 | 137 | 0.030 |
Why?
|
| Mice, Inbred Strains | 4 | 1984 | 317 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1994 | 459 | 0.030 |
Why?
|
| Half-Life | 1 | 1993 | 159 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1994 | 136 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1994 | 351 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3448 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 1277 | 0.030 |
Why?
|
| Solubility | 2 | 1986 | 133 | 0.030 |
Why?
|
| Chromosome Disorders | 2 | 1972 | 310 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 1068 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1994 | 197 | 0.030 |
Why?
|
| Chromosome Aberrations | 3 | 1972 | 617 | 0.030 |
Why?
|
| Codon | 1 | 1992 | 97 | 0.020 |
Why?
|
| DEAE-Dextran | 3 | 1977 | 5 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1974 | 230 | 0.020 |
Why?
|
| Baculoviridae | 1 | 1991 | 64 | 0.020 |
Why?
|
| Microsomes | 1 | 1991 | 56 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1991 | 64 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1996 | 1166 | 0.020 |
Why?
|
| Insecta | 1 | 1991 | 57 | 0.020 |
Why?
|
| Deoxyglucose | 3 | 1976 | 30 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1999 | 1890 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 1680 | 0.020 |
Why?
|
| Colchicine | 1 | 1991 | 42 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 570 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 5 | 1998 | 4366 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1991 | 59 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 142 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1991 | 83 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1991 | 77 | 0.020 |
Why?
|
| Proviruses | 1 | 1990 | 18 | 0.020 |
Why?
|
| Aldosterone | 1 | 1990 | 59 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 792 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 1424 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1991 | 150 | 0.020 |
Why?
|
| Microtubules | 1 | 1991 | 195 | 0.020 |
Why?
|
| Hybrid Cells | 2 | 1988 | 81 | 0.020 |
Why?
|
| Hepatitis C | 1 | 1994 | 368 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1990 | 312 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2010 | 112 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1991 | 356 | 0.020 |
Why?
|
| Lung | 4 | 1971 | 1476 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 449 | 0.020 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 1987 | 382 | 0.020 |
Why?
|
| 1-Butanol | 1 | 1989 | 1 | 0.020 |
Why?
|
| Peptide Fragments | 3 | 1994 | 745 | 0.020 |
Why?
|
| Poly A | 2 | 1979 | 60 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 30 | 0.020 |
Why?
|
| Carbohydrate Conformation | 1 | 1988 | 16 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1989 | 284 | 0.020 |
Why?
|
| Antimetabolites | 2 | 1965 | 32 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 1988 | 43 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 55 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 49 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 636 | 0.020 |
Why?
|
| Survival Rate | 1 | 1994 | 1997 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1991 | 248 | 0.020 |
Why?
|
| Papio ursinus | 1 | 2008 | 1 | 0.020 |
Why?
|
| Papio anubis | 1 | 2008 | 2 | 0.020 |
Why?
|
| Papio cynocephalus | 1 | 2008 | 3 | 0.020 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 11 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2008 | 33 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 2 | 1978 | 15 | 0.020 |
Why?
|
| Monensin | 1 | 1987 | 10 | 0.020 |
Why?
|
| United States | 1 | 2003 | 10487 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 337 | 0.020 |
Why?
|
| Crohn Disease | 1 | 1991 | 281 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 1987 | 92 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2007 | 56 | 0.020 |
Why?
|
| Immunoassay | 1 | 1987 | 127 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1987 | 138 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 522 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 1986 | 19 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Metaplasia | 1 | 1987 | 213 | 0.020 |
Why?
|
| Transcription Factors | 1 | 1996 | 2577 | 0.020 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1986 | 9 | 0.020 |
Why?
|
| Research | 5 | 1965 | 261 | 0.020 |
Why?
|
| Genetic Code | 2 | 1999 | 40 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 1989 | 446 | 0.020 |
Why?
|
| Viral Fusion Proteins | 1 | 1986 | 77 | 0.020 |
Why?
|
| Costa Rica | 1 | 2005 | 10 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2005 | 4 | 0.020 |
Why?
|
| RNA | 2 | 1985 | 578 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 1234 | 0.020 |
Why?
|
| Germinal Center | 1 | 2005 | 37 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1985 | 11 | 0.020 |
Why?
|
| Prognosis | 1 | 1995 | 4488 | 0.020 |
Why?
|
| Tunicamycin | 1 | 1985 | 8 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1985 | 43 | 0.020 |
Why?
|
| Glucosamine | 1 | 1985 | 10 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 1985 | 15 | 0.020 |
Why?
|
| Mannose | 1 | 1985 | 19 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1985 | 186 | 0.020 |
Why?
|
| Exocytosis | 1 | 1985 | 64 | 0.020 |
Why?
|
| Rats | 2 | 1997 | 3657 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1985 | 204 | 0.020 |
Why?
|
| Polyomaviridae | 3 | 1974 | 3 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1986 | 213 | 0.010 |
Why?
|
| Octoxynol | 1 | 1984 | 7 | 0.010 |
Why?
|
| Leupeptins | 1 | 1984 | 26 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 137 | 0.010 |
Why?
|
| Iodoproteins | 1 | 1984 | 1 | 0.010 |
Why?
|
| Growth Substances | 1 | 1984 | 113 | 0.010 |
Why?
|
| Glycosides | 1 | 1983 | 7 | 0.010 |
Why?
|
| Fucose | 1 | 1983 | 21 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 1997 | 1354 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1987 | 1227 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1985 | 288 | 0.010 |
Why?
|
| Microinjections | 2 | 1997 | 53 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1995 | 8096 | 0.010 |
Why?
|
| Isoelectric Point | 2 | 1980 | 18 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1984 | 217 | 0.010 |
Why?
|
| Papilloma | 2 | 1973 | 25 | 0.010 |
Why?
|
| Nephritis | 1 | 2002 | 20 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1982 | 26 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 2 | 1973 | 77 | 0.010 |
Why?
|
| Cystitis | 1 | 2002 | 50 | 0.010 |
Why?
|
| Glycopeptides | 1 | 1981 | 26 | 0.010 |
Why?
|
| Pituitary Hormones | 1 | 1981 | 3 | 0.010 |
Why?
|
| Urethane | 1 | 1981 | 5 | 0.010 |
Why?
|
| Methylcellulose | 1 | 1981 | 5 | 0.010 |
Why?
|
| X-Rays | 1 | 1981 | 26 | 0.010 |
Why?
|
| Subcellular Fractions | 2 | 1979 | 98 | 0.010 |
Why?
|
| Homozygote | 2 | 1993 | 521 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 1490 | 0.010 |
Why?
|
| Tissue Culture Techniques | 3 | 1965 | 70 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 680 | 0.010 |
Why?
|
| Amino Acids | 1 | 1983 | 660 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1980 | 3 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 2933 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 1246 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1980 | 38 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1980 | 110 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3307 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2000 | 84 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 1109 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 536 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1980 | 98 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2000 | 156 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2002 | 457 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1978 | 46 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 3 | 1972 | 330 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1999 | 79 | 0.010 |
Why?
|
| Calcium | 1 | 1984 | 1095 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 1978 | 3 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1989 | 106 | 0.010 |
Why?
|
| In Vitro Techniques | 3 | 1997 | 968 | 0.010 |
Why?
|
| Tritium | 3 | 1974 | 174 | 0.010 |
Why?
|
| Calcium Chloride | 1 | 1977 | 22 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1977 | 87 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 78 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1978 | 135 | 0.010 |
Why?
|
| Symbiosis | 1 | 1998 | 65 | 0.010 |
Why?
|
| Rod Opsins | 1 | 1997 | 16 | 0.010 |
Why?
|
| Viral Interference | 1 | 1977 | 6 | 0.010 |
Why?
|
| Peptide Biosynthesis | 1 | 1977 | 19 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1977 | 119 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 124 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1997 | 30 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 38 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1997 | 102 | 0.010 |
Why?
|
| Cells | 1 | 1977 | 27 | 0.010 |
Why?
|
| Retroviridae | 1 | 1977 | 205 | 0.010 |
Why?
|
| Antibodies | 2 | 1971 | 371 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1999 | 346 | 0.010 |
Why?
|
| Warts | 2 | 1973 | 11 | 0.010 |
Why?
|
| Agglutination | 1 | 1976 | 3 | 0.010 |
Why?
|
| Detergents | 1 | 1976 | 23 | 0.010 |
Why?
|
| Deoxyribonucleases | 2 | 1974 | 26 | 0.010 |
Why?
|
| Proteins | 1 | 1982 | 1043 | 0.010 |
Why?
|
| Dextrans | 2 | 1974 | 45 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1997 | 286 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 1296 | 0.010 |
Why?
|
| Morphogenesis | 2 | 1989 | 212 | 0.010 |
Why?
|
| Adenoviridae Infections | 2 | 1966 | 69 | 0.010 |
Why?
|
| Thymidine | 2 | 1974 | 55 | 0.010 |
Why?
|
| 5-Methylcytosine | 2 | 1987 | 32 | 0.010 |
Why?
|
| Minor Lymphocyte Stimulatory Antigens | 1 | 1995 | 1 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 3 | 1974 | 97 | 0.010 |
Why?
|
| Cross Reactions | 2 | 1973 | 192 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1997 | 697 | 0.010 |
Why?
|
| Gene Products, rev | 1 | 1995 | 11 | 0.010 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 17 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1995 | 28 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 31 | 0.010 |
Why?
|
| Contact Inhibition | 1 | 1975 | 2 | 0.010 |
Why?
|
| Potassium | 1 | 1976 | 279 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1975 | 89 | 0.010 |
Why?
|
| Surface Properties | 1 | 1975 | 76 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1975 | 53 | 0.010 |
Why?
|
| DNA Damage | 1 | 1998 | 516 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 244 | 0.010 |
Why?
|
| Mumps virus | 1 | 1974 | 4 | 0.010 |
Why?
|
| Parotitis | 1 | 1974 | 5 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1974 | 65 | 0.010 |
Why?
|
| Dimethylnitrosamine | 1 | 1993 | 2 | 0.010 |
Why?
|
| Eye Abnormalities | 1 | 1994 | 105 | 0.010 |
Why?
|
| Condylomata Acuminata | 1 | 1973 | 15 | 0.010 |
Why?
|
| Meningitis | 1 | 1974 | 99 | 0.010 |
Why?
|
| Fibroma | 1 | 1973 | 30 | 0.010 |
Why?
|
| Radiation Effects | 1 | 1973 | 16 | 0.010 |
Why?
|
| Eye | 1 | 1994 | 227 | 0.010 |
Why?
|
| Adenovirus Early Proteins | 1 | 1992 | 4 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1995 | 1104 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 150 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1972 | 43 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1992 | 30 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1972 | 51 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 768 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1972 | 34 | 0.010 |
Why?
|
| Blastocyst | 1 | 1992 | 76 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1992 | 122 | 0.010 |
Why?
|
| Skin | 1 | 1975 | 503 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1971 | 19 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1974 | 326 | 0.010 |
Why?
|
| Idoxuridine | 2 | 1973 | 6 | 0.010 |
Why?
|
| Acute Disease | 1 | 1974 | 1090 | 0.010 |
Why?
|
| Exons | 1 | 1992 | 793 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1991 | 313 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1989 | 193 | 0.000 |
Why?
|
| Gentamicins | 1 | 1989 | 95 | 0.000 |
Why?
|
| Histones | 1 | 1992 | 530 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1971 | 1007 | 0.000 |
Why?
|
| Stem Cells | 1 | 1992 | 710 | 0.000 |
Why?
|
| Genetics | 1 | 1967 | 23 | 0.000 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1991 | 457 | 0.000 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1986 | 6 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 1994 | 3770 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1986 | 105 | 0.000 |
Why?
|
| Floxuridine | 1 | 1965 | 9 | 0.000 |
Why?
|
| Puromycin | 1 | 1965 | 11 | 0.000 |
Why?
|
| Nucleosides | 1 | 1965 | 17 | 0.000 |
Why?
|
| Pharmacology | 1 | 1965 | 10 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1965 | 68 | 0.000 |
Why?
|
| Fluorescence | 1 | 1965 | 93 | 0.000 |
Why?
|
| Mitomycin | 1 | 1965 | 50 | 0.000 |
Why?
|
| Phenylalanine | 1 | 1965 | 122 | 0.000 |
Why?
|
| Fluorouracil | 1 | 1965 | 140 | 0.000 |
Why?
|
| Microscopy | 1 | 1965 | 119 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1986 | 621 | 0.000 |
Why?
|
| Hormones | 1 | 1985 | 189 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1983 | 41 | 0.000 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1985 | 212 | 0.000 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 1974 | 44 | 0.000 |
Why?
|
| Cell Aggregation | 1 | 1981 | 23 | 0.000 |
Why?
|
| RNA Splicing | 1 | 1983 | 223 | 0.000 |
Why?
|
| Body Weight | 1 | 1985 | 963 | 0.000 |
Why?
|
| Castration | 1 | 1980 | 31 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1980 | 46 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1989 | 2385 | 0.000 |
Why?
|
| Ovary | 1 | 1980 | 390 | 0.000 |
Why?
|
| Pronase | 1 | 1974 | 4 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1974 | 23 | 0.000 |
Why?
|
| Ribonucleases | 1 | 1974 | 55 | 0.000 |
Why?
|
| Trypsin | 1 | 1974 | 95 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1974 | 75 | 0.000 |
Why?
|
| Laryngeal Diseases | 1 | 1973 | 30 | 0.000 |
Why?
|
| Phenols | 1 | 1974 | 57 | 0.000 |
Why?
|
| Genital Diseases, Male | 1 | 1973 | 12 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1974 | 186 | 0.000 |
Why?
|
| Genital Diseases, Female | 1 | 1973 | 32 | 0.000 |
Why?
|
| Pancreas | 1 | 1974 | 214 | 0.000 |
Why?
|
| Dogs | 1 | 1974 | 761 | 0.000 |
Why?
|
| Cattle | 1 | 1974 | 555 | 0.000 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1973 | 93 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1974 | 226 | 0.000 |
Why?
|
| Uridine | 1 | 1971 | 34 | 0.000 |
Why?
|
| Pregnancy Complications | 1 | 1973 | 503 | 0.000 |
Why?
|
| Measles virus | 1 | 1966 | 10 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1966 | 110 | 0.000 |
Why?
|